CN104918955B - Fcγ受体IIB变体 - Google Patents

Fcγ受体IIB变体 Download PDF

Info

Publication number
CN104918955B
CN104918955B CN201380056738.3A CN201380056738A CN104918955B CN 104918955 B CN104918955 B CN 104918955B CN 201380056738 A CN201380056738 A CN 201380056738A CN 104918955 B CN104918955 B CN 104918955B
Authority
CN
China
Prior art keywords
seq
protein
nucleic acid
host cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380056738.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104918955A (zh
Inventor
P·松德尔曼
D·特米尔
T·波尔
R·温特
U·雅各布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suppremol GmbH
Original Assignee
Suppremol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol GmbH filed Critical Suppremol GmbH
Publication of CN104918955A publication Critical patent/CN104918955A/zh
Application granted granted Critical
Publication of CN104918955B publication Critical patent/CN104918955B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
CN201380056738.3A 2012-10-30 2013-10-30 Fcγ受体IIB变体 Active CN104918955B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/663,527 2012-10-30
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Publications (2)

Publication Number Publication Date
CN104918955A CN104918955A (zh) 2015-09-16
CN104918955B true CN104918955B (zh) 2018-10-09

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380056738.3A Active CN104918955B (zh) 2012-10-30 2013-10-30 Fcγ受体IIB变体

Country Status (27)

Country Link
US (1) US10028998B2 (enExample)
EP (1) EP2914624B1 (enExample)
JP (2) JP6423351B2 (enExample)
KR (1) KR102170674B1 (enExample)
CN (1) CN104918955B (enExample)
AU (1) AU2013340831B2 (enExample)
BR (1) BR112015008815A2 (enExample)
CA (1) CA2887164C (enExample)
CL (1) CL2015001127A1 (enExample)
DK (1) DK2914624T3 (enExample)
EA (1) EA033437B9 (enExample)
ES (1) ES2628049T3 (enExample)
HR (1) HRP20170894T1 (enExample)
HU (1) HUE032786T2 (enExample)
IL (1) IL238528A (enExample)
IN (1) IN2015DN03206A (enExample)
LT (1) LT2914624T (enExample)
MX (1) MX359802B (enExample)
MY (1) MY173686A (enExample)
NZ (1) NZ706884A (enExample)
PH (1) PH12015500771B1 (enExample)
PL (1) PL2914624T3 (enExample)
PT (1) PT2914624T (enExample)
RS (1) RS56075B1 (enExample)
SG (1) SG11201502749VA (enExample)
SI (1) SI2914624T1 (enExample)
WO (1) WO2014068012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
EA034176B1 (ru) 2013-10-16 2020-01-14 Зуппремоль Гмбх РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えＦｃγＲＩＩｂ
CN112423900A (zh) * 2018-06-25 2021-02-26 巴斯夫涂料有限公司 生产优化涂层的方法和使用所述方法可获得的涂层
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002924A1 (en) * 2001-11-22 2005-01-06 Robert Huber Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III
CN1867583A (zh) * 2003-05-02 2006-11-22 赞科股份有限公司 优化的Fc变体及其产生方法
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
AU2004293184B2 (en) 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
DE602006020333D1 (de) 2005-12-13 2011-04-07 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002924A1 (en) * 2001-11-22 2005-01-06 Robert Huber Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III
CN1867583A (zh) * 2003-05-02 2006-11-22 赞科股份有限公司 优化的Fc变体及其产生方法
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P. Sondermann et al.Human Fcγ Receptor IIb Expressed in Escherichia coli Reveals IgG Binding Capability.《Biological Chemistry》.1999,第380卷(第6期), *
P.Sondermann et al.Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution.《The EMBO Journal》.1999,第18卷(第5期), *

Also Published As

Publication number Publication date
JP2016503289A (ja) 2016-02-04
JP2018186833A (ja) 2018-11-29
CN104918955A (zh) 2015-09-16
IL238528A (en) 2017-07-31
MX2015005266A (es) 2015-10-26
PL2914624T3 (pl) 2017-09-29
KR20150122621A (ko) 2015-11-02
IN2015DN03206A (enExample) 2015-10-02
WO2014068012A1 (en) 2014-05-08
CA2887164C (en) 2020-12-29
EP2914624B1 (en) 2017-03-15
PT2914624T (pt) 2017-06-07
KR102170674B1 (ko) 2020-10-28
HK1209765A1 (en) 2016-04-08
IL238528A0 (en) 2015-06-30
BR112015008815A2 (pt) 2017-11-21
EA033437B9 (ru) 2020-03-19
AU2013340831A1 (en) 2015-04-30
RS56075B1 (sr) 2017-10-31
US20140120080A1 (en) 2014-05-01
ES2628049T3 (es) 2017-08-01
EA033437B1 (ru) 2019-10-31
NZ706884A (en) 2019-05-31
AU2013340831B2 (en) 2017-11-23
CL2015001127A1 (es) 2015-12-18
EP2914624A1 (en) 2015-09-09
US10028998B2 (en) 2018-07-24
JP6423351B2 (ja) 2018-11-14
MY173686A (en) 2020-02-15
SI2914624T1 (sl) 2017-07-31
HUE032786T2 (en) 2017-10-30
HRP20170894T1 (hr) 2017-09-08
CA2887164A1 (en) 2014-05-08
PH12015500771A1 (en) 2015-06-08
LT2914624T (lt) 2017-06-26
EA201590845A1 (ru) 2015-08-31
DK2914624T3 (en) 2017-06-26
SG11201502749VA (en) 2015-05-28
MX359802B (es) 2018-10-10
PH12015500771B1 (en) 2018-12-14

Similar Documents

Publication Publication Date Title
CN104918955B (zh) Fcγ受体IIB变体
CN104968795B (zh) 增强蛋白表达的多肽
JP7071288B2 (ja) Ｔ細胞調節多量体ポリペプチド及びその使用方法
JP6567506B2 (ja) 低下した又はサイレント化したエフェクター機能を持つヘテロ多量体
KR20190044029A (ko) 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
CN116970060A (zh) T细胞调节性多聚体多肽及其使用方法
KR20090090295A (ko) 눈물 리포칼린 돌연변이 단백질 및 이를 얻는 방법
EP4190906B1 (en) Engineered polypeptides derived from adenoviral fibre protein and vlps containing the polypeptides
US20130224238A1 (en) Gpcr as vaccines or for removing/inhibiting autoantibodies, toxins or ligands binding to the gpcr
US20230414777A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
TW200848071A (en) Immunoglobulin fusion proteins and methods of making
WO2016085820A1 (en) Lysosomal targeting and uses thereof
US10669324B2 (en) Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US20150166609A1 (en) Fusion expression of g-protein coupled receptor
US8124097B2 (en) Hybrid and chimeric polypeptides that regulate activation of complement
HK1209765B (en) Fc gamma receptor iib variants
Zhang Structural-Based Study of Intact Human Particulate Guanylyl Cyclase Receptor A (pGC-A) and Biophysical Characterization
WO2024006576A1 (en) Mhc class ii protein constructs
WO2026050634A1 (en) Butyrophilin a2 for inhibition of b cell activation and/or for prolonged humoral suppression or humoral tolerance
JP2026508395A (ja) 自己免疫及び炎症の処置のためのブチロフィリンａ２及び関連アイソフォーム
Plewnia Biochemical and biophysical characterization of extrinsic and intrinsic modulators of the antigen transporter TAP

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant